DOCSLIB.ORG

Annual Report 2004 Annual Report 2004 Annual Report 2004

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Annual Report 2004 Annual Report 2004 Annual Report 2004 FUJISAWA PHARMACEUTICAL COMPANY LIMITED COMPANY PHARMACEUTICAL FUJISAWA FUJISAWA PHARMACEUTICAL COMPANY LIMITED PHARMACEUTICAL FUJISAWA ANNUAL REPORT 2004 ANNUAL REPORT 2004 REPORT ANNUAL ANNUAL REPORT 2004 ANNUAL REPORT Printed on recycled paper in Japan C4 C1 04.07/藤沢薬品 AR 04 表1-4 YMCB Fujisawa Pharmaceutical Co., Ltd., headquartered in Japan, is a research-driven pharmaceutical company with a firm commitment to innovative research in its quest to satisfy unmet medical needs and contribute to the progress of medical care. Corporate Mission “Fujisawa contributes to healthier, more prosperous lives for people around the world by exploring the frontiers of human health and disease.” CONTENTS The F-mark, Fujisawa’s logo, encapsulates Fujisawa’s desire to share the Financial Highlights/1 Highlights of the Year/2 joy of good health with people all over the world. Message from the President/4 Red: Passionate commitment to research and development Global Network/8 Major Products/10 Blue: Pursuit of purity and quality People-our most precious resource/12 Ethical Pharmaceuticals Business/14 Yellow: Desire to improve the health and lives of people everywhere Japan/14 North America/15 Europe/16 Under the banner of the F-mark, Fujisawa will continue to help people Asia/17 live healthy, satisfying lives. R&D Network/18 Research/21 Products under Clinical Development/22 Tremendous progress has been made in the biomedical sciences in Development/23 Health Care/24 recent years. In an attempt to summarize in a few words the essence of Production Network/26 Production/27 Fujisawa’s corporate philosophy, we have coined the corporate slogan Environmental Protection/28 “New Medicines for New Times.” Board of Directors/Top Management with Global Functional Heads/30 Review of the Year/31 Management and Corporate Auditors/ Corporate Directory/55 Investor Information/57 Brief History/58 Fujisawa Pharmaceutical Company Limited and Consolidated Subsidiaries Financial Highlights Years ended March 31 Millions of yen Thousands of U.S. dollars* 2004 2003 2004 Change (%) Net sales ........................................ ¥395,401 ¥382,079 $3,730,198 103.5 Income before income taxes ................. 69,138 44,690 652,245 154.7 Net income ..................................... 41,468 28,635 391,208 144.8 Shareholders’ equity .......................... 375,944 335,337 3,546,642 112.1 Amounts per share (in yen and dollars): Net income Basic ..................................... ¥ 125.63 ¥ 86.62 $ 1.19 145.0 Diluted .................................. 123.65 85.37 1.17 144.8 Cash dividends ............................. 22.00 18.00 0.21 122.2 Total assets .................................... ¥499,693 ¥511,516 $4,714,085 97.7 Research and development expenses ....... 73,643 62,426 694,745 118.0 * The U.S. dollar amounts in this report represent, for convenience only, translations of Japanese yen at the rate of ¥106=US$1. Net Sales Operating Income Net Income (¥ bn) (¥ bn) (%) (¥ bn) (%) 400 395.4 70 20 45 15 382.1 41.5 62.1 341.4 320 56 16.3 56.7 16 36 12 289.1 297.5 13.7 14.3 10.5 28.6 240 42 12.1 11.3 46.9 12 27 26.2 9 7.9 34.8 33.6 6.9 7.5 22.9 7.7 160 28 8 18 20.5 6 80 14 4 9 3 0 0 0 0 0 2000 2001 2002 2003 2004 2000 2001 2002 2003 2004 2000 2001 2002 2003 2004 Operating Income Net Income Ratio to Net Sales Ratio to Net Sales Statements made in this annual report with respect to Fujisawa’s current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Fujisawa. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. Consequently, undue reliance should not be placed on these statements. Fujisawa cautions the reader that a number of important factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions in, and the Pharmaceutical Affairs Law and other laws and regulations relating to, Fujisawa’s markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Fujisawa to market existing and new products effectively, (v) Fujisawa’s ability to continue to research and develop products accepted by customers in highly competitive markets and (vi) infringements of Fujisawa’s intellectual property rights. 1 Highlights of the Year (For the Year ended March 31) Fujisawa established new highs in business performance — net sales of ¥395,401 million (US$3,730 million) and net income of ¥41,468 million (US$391 million). Firm sales growth of Fujisawa Healthcare, Inc. and Fujisawa GmbH contributed significantly to Fujisawa’s business performance. Overseas business accounted for 48.6% of total revenue. ® Our No. 1 product Prograf achieved 16% sales growth with ¥104 billion (US$985 million) and is further strengthening its position as the cornerstone immunosuppressant for organ transplantation. ® Protopic is now commercially available in almost 30 countries. The global ® marketing of Protopic achieved a 33% sales jump over the previous term. R&D Expenses Capital Expenses Total Assets (¥ bn) (%) (¥ bn) (¥ bn) 75 73.6 25 30 550 511.5 499.7 462.3 474.5 60 20 24.4 62.4 24 440 421.7 17.5 57.1 18.6 21.2 19.8 19.7 20.4 20.3 45 15.8 52.0 15 16.7 16.3 18 330 45.6 16.1 15.6 15.4 30 10 12 12.9 220 15 5 6 110 0 0 0 0 2000 2001 2002 2003 2004 2000 2001 2002 2003 2004 2000 2001 2002 2003 2004 R&D Expenses Acquisition of Property, Plant Ratio to Net Sales and Equipment Depreciation and Amortization 2 Micafungin, Fujisawa’s third global product, has been well accepted since its debut as Funguard® for Infusion in Japan, and recorded ¥11 billion (US$105 million) sales. Under the Global Headquarters, a newly established global management system in April 2003, the local operations are involved on an equal footing in decision-making and execution of the global agenda. In the three Chinese-speaking economies of China, Hong Kong and Taiwan,we reorganized our operations effective April 1, 2004 in order to improve operational efficiency and profitability in these markets. On June 24, 2004 the shareholders of Fujisawa and Yamanouchi Pharmaceutical Co., Ltd., respectively, approved a definitive agreement on the merger of the two companies leading the creation of Astellas Pharma Inc. effective April 1, 2005. Return on Equity Earnings per Share Overseas Sales Ratio (%) (¥) (%) 15 150 50 46.7 48.6 44.1 125.63 12 11.7 120 40 35.3 36.3 9.5 9 8.8 90 30 7.8 8.8 86.62 71.09 80.07 6 60 63.62 20 3 30 10 0 0 0 2000 2001 2002 2003 2004 2000 2001 2002 2003 2004 2000 2001 2002 2003 2004 3 Message from the President I am very pleased to present Fujisawa’s annual report for the year ended March 31, 2004. The term under review was highlighted by the announcement of our planned merger with Yamanouchi Pharmaceutical Co., Ltd., and we also made many other strategic decisions to focus our management resources more effectively on our healthcare platform, thus ensuring sustainable growth over the long term. Progress of Our Business Net sales increased by 3.5% to ¥395,401 million (US$3,730 million) over the previous year, setting a new record. Key drivers of this growth once again are the continuing growth of our two major subsidiaries, Fujisawa Healthcare, Inc. and Fujisawa GmbH, both led by the immunosuppressant Prograf® (tacrolimus). As for sales of individual products, consolidated sales of Prograf® surpassed ¥100 billion for the first time. With ¥104.4 billion (US$985 million), a 16% increase over the previous fiscal year, Prograf® has become the first ¥100 billion product in Fujisawa’s history. The injectable antifungal agent Funguard® for Infusion (micafungin) also achieved sales of ¥11.1 billion (US$105 million) for its first full year in Japan after its launch in December 2002. Funguard® has become the number one injectable antifungal agent in Japan. We also successfully launched the ketoride class oral antibiotic Ketek® (telithromycin) in Japan in December 2003. While operating income, at ¥56,703 million (US$535 million), recorded an 8.8% year-on-year decrease, mainly due to heavy investments in research and development, recognition of extraordinary gains caused net income to rise 44.8% to ¥41,468 million (US$391 million). We announced our long-term management strategy “VISION 2005” in the fiscal year ended March 31, 2000. Over the subsequent four years from April 1, 2000, in pursuit of our targets Progress under VISION 2005 Return on Equity 11.7% 10.0% Net Sales 9.5% Overseas Sales 8.8% (¥bn) Japanese Sales 7.8% 8.8% 400 400 Net Income 300 200 100 40 0 Years to March 31 2000 2001 2002 2003 2004 2006 4 under this strategy, we have achieved growth of 8.1% and 12.9% on a compounded annual growth rate basis for net sales and operating income, respectively. Total overseas sales, at ¥192.1 billion (US$1,813 million), were up even more sharply, recording compounded annual growth of 17.1% over the same four-year period. I believe this is clear evidence that we have implemented the right strategies to improve the corporate value of Fujisawa under VISION 2005. Progress in Research and Development We are committed to sustaining a high level of spending on research and development while taking profitability constantly into account.
Load more

Recommended publications
  • View a Copy of This Licence, Visit Tivecommons.Org/Licenses/By/4.0
    Katakami et al. Cardiovasc Diabetol (2020) 19:110 https://doi.org/10.1186/s12933-020-01079-4 Cardiovascular Diabetology ORIGINAL INVESTIGATION Open Access Tofoglifozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study Naoto Katakami1,2* , Tomoya Mita3, Hidenori Yoshii4, Toshihiko Shiraiwa5, Tetsuyuki Yasuda6, Yosuke Okada7, Keiichi Torimoto7, Yutaka Umayahara8, Hideaki Kaneto9, Takeshi Osonoi10, Tsunehiko Yamamoto11, Nobuichi Kuribayashi12, Kazuhisa Maeda13, Hiroki Yokoyama14, Keisuke Kosugi15, Kentaro Ohtoshi16, Isao Hayashi17, Satoru Sumitani18, Mamiko Tsugawa19, Kayoko Ryomoto20, Hideki Taki21, Tadashi Nakamura22, Satoshi Kawashima23, Yasunori Sato24, Hirotaka Watada3 and Iichiro Shimomura1 on behalf of the UTOPIA study investigators Abstract Background: This study aimed to investigate the preventive efects of tofoglifozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression in type 2 diabetes (T2DM) patients without apparent cardiovascular disease (CVD) by monitoring carotid intima-media thickness (IMT). Methods: This prospective, randomized, open-label, blinded-endpoint, multicenter, parallel-group, comparative study included 340 subjects with T2DM and no history of apparent CVD recruited at 24 clinical units. Subjects were randomly allocated to either the tofoglifozin treatment group (n 169) or conventional treatment group using drugs other than SGLT2 inhibitors (n 171). Primary outcomes were changes= in mean and maximum common carotid IMT measured by echography during= a 104-week treatment period. Results: In a mixed-efects model for repeated measures, the mean IMT of the common carotid artery (mean- IMT-CCA), along with the right and left maximum IMT of the CCA (max-IMT-CCA), signifcantly declined in both the tofoglifozin ( 0.132 mm, SE 0.007; 0.163 mm, SE 0.013; 0.170 mm, SE 0.020, respectively) and the control group ( 0.140 mm,− SE 0.006; 0.190 mm,− SE 0.012; 0.190 mm,− SE 0.020, respectively).
    [Show full text]
  • Ranking of Stocks by Market Capitalization(As of End of Mar.2020)
    Ranking of Stocks by Market Capitalization(As of End of Mar.2020) 1st Section Rank Code Issue Market Capitalization \100mil. 1 7203 TOYOTA MOTOR CORPORATION 212,127 2 9437 NTT DOCOMO,INC. 112,630 3 6861 KEYENCE CORPORATION 84,709 4 6758 SONY CORPORATION 81,786 5 9984 SoftBank Group Corp. 79,162 6 9433 KDDI CORPORATION 75,136 7 4519 CHUGAI PHARMACEUTICAL CO.,LTD. 69,960 8 9432 NIPPON TELEGRAPH AND TELEPHONE CORPORATION 68,006 9 9434 SoftBank Corp. 65,799 10 7974 Nintendo Co.,Ltd. 54,787 11 8306 Mitsubishi UFJ Financial Group,Inc. 54,735 12 4568 DAIICHI SANKYO COMPANY,LIMITED 52,707 13 4502 Takeda Pharmaceutical Company Limited 52,146 14 4661 ORIENTAL LAND CO.,LTD. 50,261 15 6098 Recruit Holdings Co.,Ltd. 47,419 16 9983 FAST RETAILING CO.,LTD. 46,873 17 7182 JAPAN POST BANK Co.,Ltd. 44,865 18 4063 Shin-Etsu Chemical Co.,Ltd. 44,707 19 7267 HONDA MOTOR CO.,LTD. 44,017 20 4452 Kao Corporation 42,560 21 6367 DAIKIN INDUSTRIES,LTD. 38,603 22 6981 Murata Manufacturing Co.,Ltd. 36,980 23 8058 Mitsubishi Corporation 36,436 24 8316 Sumitomo Mitsui Financial Group,Inc. 36,018 25 9022 Central Japan Railway Company 35,679 26 8001 ITOCHU Corporation 35,541 27 8766 Tokio Marine Holdings,Inc. 35,145 28 7741 HOYA CORPORATION 34,808 29 6594 NIDEC CORPORATION 33,433 30 8035 Tokyo Electron Limited 32,000 31 3382 Seven & I Holdings Co.,Ltd. 31,699 32 7751 CANON INC. 31,463 33 8411 Mizuho Financial Group,Inc.
    [Show full text]
  • Press Release
    Press Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Sunao Manabe, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please address inquiries to Junichi Onuma, Vice President, Corporate Communications Department Telephone: +81-3-6225-1126 https://www.daiichisankyo.com Daiichi Sankyo Announces Transfer from Astellas Pharma of Three Products in Asia Tokyo, Japan (October 15, 2019) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it agreed with Astellas Pharma Inc. (hereafter, Astellas Pharma) that Astellas Pharma local subsidiaries companies in six Asian countries will transfer three products to Daiichi Sankyo. The products to be transferred and the countries where they are sold are as follows. Product Korea China Taiwan Thailand Philippines Indonesia [generic name (brand name)] Ramosetron Antiemetic ○ ○ ○ ○ (Nasea) Nicardipine Anti- ○ ○ ○ (Perdipine) hypertensive Barnidipine Anti- ○ (Oldeca) hypertensive ○ indicate the countries where the products are sold The antiemetics are expected to have synergistic effects with mirogabalin and the cancer drugs that Daiichi Sankyo is currently developing in Asia, and the two antihypertensives are expected to effectively utilize Daiichi Sankyo’s current infrastructures in combination with its cardiovascular products, such as olmesartan and edoxaban. The total net sales of Astellas Pharma's three products in fiscal year 2018 were approximately 5.0 billion yen. 1 Daiichi Sankyo will take over the rights
    [Show full text]
  • R&Co Risk-Based International Index – Weighting
    Rothschild & Co Risk-Based International Index Indicative Index Weight Data as of June 30, 2021 on close Constituent Exchange Country Index Weight(%) Jardine Matheson Holdings Ltd Singapore 1.46 LEG Immobilien SE Germany 0.98 Ajinomoto Co Inc Japan 0.95 SoftBank Corp Japan 0.89 Shimano Inc Japan 0.85 FUJIFILM Holdings Corp Japan 0.73 Singapore Exchange Ltd Singapore 0.72 Japan Tobacco Inc Japan 0.72 Cellnex Telecom SA Spain 0.69 Nintendo Co Ltd Japan 0.69 Carrefour SA France 0.67 Nexon Co Ltd Japan 0.66 Deutsche Wohnen SE Germany 0.65 Bank of China Ltd Hong Kong 0.64 REN - Redes Energeticas Nacion Portugal 0.63 Pan Pacific International Hold Japan 0.63 Japan Post Holdings Co Ltd Japan 0.62 Nippon Telegraph & Telephone C Japan 0.61 Roche Holding AG Switzerland 0.61 Nestle SA Switzerland 0.61 Novo Nordisk A/S Denmark 0.59 ENEOS Holdings Inc Japan 0.59 Nomura Research Institute Ltd Japan 0.59 Koninklijke Ahold Delhaize NV Netherlands 0.59 Jeronimo Martins SGPS SA Portugal 0.58 HelloFresh SE Germany 0.58 Toshiba Corp Japan 0.58 Hoya Corp Japan 0.58 Siemens Healthineers AG Germany 0.58 MS&AD Insurance Group Holdings Japan 0.57 Coloplast A/S Denmark 0.57 Kerry Group PLC Ireland 0.57 Scout24 AG Germany 0.57 SG Holdings Co Ltd Japan 0.56 Symrise AG Germany 0.56 Nitori Holdings Co Ltd Japan 0.56 Beiersdorf AG Germany 0.55 Mitsubishi Corp Japan 0.55 KDDI Corp Japan 0.55 Sysmex Corp Japan 0.55 Chr Hansen Holding A/S Denmark 0.55 Ping An Insurance Group Co of Hong Kong 0.55 Eisai Co Ltd Japan 0.54 Chocoladefabriken Lindt & Spru Switzerland 0.54 Givaudan
    [Show full text]
  • Association Between Variability in Body Mass Index and Development of Type 2 Diabetes: Panasonic Cohort Study
    Epidemiology/Health services research Open access Original research BMJ Open Diab Res Care: first published as 10.1136/bmjdrc-2021-002123 on 22 April 2021. Downloaded from Association between variability in body mass index and development of type 2 diabetes: Panasonic cohort study Hiroshi Okada ,1 Masahide Hamaguchi ,2 Momoko Habu,1 Kazushiro Kurogi,3 Hiroaki Murata,4 Masato Ito,3 Michiaki Fukui2 To cite: Okada H, ABSTRACT Hamaguchi M, Habu M, Introduction Contrasting results have been reported for Significance of this study et al. Association between the association between the variability in body weight variability in body mass index and development of diabetes. In the present study, we What is already known about this subject? and development of type 2 evaluated the association between the variability in body ► Obesity or body weight gain accelerate the develop- diabetes: Panasonic cohort ment of diabetes. study. BMJ Open Diab Res Care mass index (BMI) and development of type 2 diabetes in 19 412 Japanese participants without obesity and without ► The association between the variability in body 2021;9:e002123. doi:10.1136/ weight and development of diabetes is controversial. bmjdrc-2021-002123 body weight gain or loss during the study period. Research design and methods We recorded body weight What are the new findings? of the participants consecutively each year in Panasonic ► The risk for developing diabetes increased by 11.1% Received 9 January 2021 Corporation, Osaka, Japan from 2008 to 2014 to evaluate Revised 26 February 2021 per 1% increase in coefficient of variation of body the variability of BMI. The participants with obesity (BMI mass index (BMI).
    [Show full text]
  • Notice of the Ordinary General Meeting of Shareholders to Be Held on June 26, 2020
    SONY CORPORATION Notice of the Ordinary General Meeting of Shareholders to be held on June 26, 2020 To the Registered Holders of American Depositary Receipts representing shares of Common Stock of Sony Corporation (the “Corporation”): The undersigned Depositary has received a notice that the Corporation has called an ordinary general meeting of shareholders to be held in Tokyo, Japan on June 26, 2020 (the “Meeting”) for the following purposes: MATTERS TO BE REPORTED: To receive reports on the business report, non-consolidated financial statements, consolidated financial statements, as well as audit reports on the consolidated financial statements by the Independent Auditors (certified public accountants) and the Audit Committee for the fiscal year ended March 31, 2020 (from April 1, 2019 to March 31, 2020) pursuant to the Companies Act of Japan. PROPOSALS TO BE ACTED UPON: 1. To amend a part of the Articles of Incorporation. 2. To elect 12 Directors. 3. To issue Stock Acquisition Rights for the purpose of granting stock options. EXPLANATION REGARDING THE SUBJECT MATTER OF THE MEETING MATTERS TO BE REPORTED: To receive reports on the business report, non-consolidated financial statements, consolidated financial statements, as well as audit reports on the consolidated financial statements by the Independent Auditors (certified public accountants) and the Audit Committee for the fiscal year ended March 31, 2020 (from April 1, 2019 to March 31, 2020). Note: The Consolidated Financial Statements pursuant to the Companies Act of Japan (Translation) are available on the Sony Investor Relations website. This document can be accessed at https://www.sony.net/SonyInfo/IR/stock/shareholders_meeting/Meeting103/ 1 PROPOSALS TO BE ACTED UPON: 1.
    [Show full text]
  • Astellas Pharma Inc. 2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, Japan Astellas Pharma Inc
    ANNUAL REPORT 2016 ANNUAL REPORT 2016 For the Year Ended March 31, 2016 Astellas Pharma Inc. 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo 103-8411, Japan http://www.astellas.com/en/ Astellas Pharma Inc. Please direct inquiries concerning Annual Report 2016 to: Astellas Pharma Inc. Corporate Communications TEL: +81-3-3244-3202 FAX: +81-3-5201-7473 This report is printed with environmentally friendly vegetable-based inks on FSCTM-certified paper made of wood sourced from responsibly managed forests, Issued in August 2016 using a waterless printing process. Printed in Japan Contents About Astellas 1 About Astellas 2 Business Philosophy Retracing Astellas’ Steps 3 Astellas Today 5 Contribute toward Health Financial and Non-Financial Highlights 7 Raison D'être Editorial Policy 9 Contribute toward improving the health of people through Innovative Drugs around the world through the provision of innovative 2 Our Strategy 10 and reliable pharmaceutical products 1 Astellas Value Creation Process 11 • To go beyond all others in exploring and tapping the potential CEO Message Astellas is concentrating on the 13 of the life sciences. CSR-Based Management 17 innovative drug business, where Business Environment 19 • To continue tackling new challenges and creating innovative it possesses key strengths. Strategic Plan 2015-2017 pharmaceutical products. 20 We are enhancing our ability to Financial Strategy 24 • To deliver quality products along with accurate information Management Structure 25 and retain solid credibility among customers. continuously develop innovative Interview with an Outside Director 27 drugs, in conjunction with • To support healthy living for people around the world. optimizing the allocation of • To continue shining on the global pharmaceutical field.
    [Show full text]
  • INTA Corporate Member List
    Corporate Members Name City State Country 100x Group Hong Kong Hong Kong 1661, Inc. Los Angeles California United States 1-800-Flowers.com, Inc. Carle Place New York United States 3M China Ltd. Shanghai Shanghai China 3M Company Saint Paul Minnesota United States 3M Deutschland GmbH Neuss Germany 3M India Ltd. Bangalore Karnataka India 3M Innovation Singapore Pte Ltd Singapore Singapore 3M KCI San Antonio Texas United States 3M United Kingdom PLC Bracknell Bracknell Forest United Kingdom 7-Eleven, Inc. Irving Texas United States AB Electrolux Stockholm Stockholms län Sweden Västra Götalands AB Volvo Göteborg län Sweden ABB ASEA Brown Boveri Ltd. Zürich Zürich Switzerland Abbott St.Paul Minnesota United States Abbott Laboratories Abbott Park Illinois United States Abbott Products Operations AG Allschwil Switzerland AbbVie Inc. Irvine California United States AbbVie Inc. North Chicago Illinois United States Abercrombie & Fitch Co. New Albany Ohio United States ABRO Industries, Inc. South Bend Indiana United States ACCO Brands Corporation Lake Zurich Illinois United States Activision Blizzard UK Ltd. Slough United Kingdom Activision Blizzard, Inc. Santa Monica California United States Activision Computer Technology Co. Ltd. Shanghai Shanghai China Acushnet Company Fairhaven Massachusetts United States Aderans America Holdings, Inc. Beverly Hills California United States adidas Group Panama Panamá Panama Adidas Group, India Gurgaon Haryana India adidas International Marketing BV Amsterdam Netherlands adidas International, Inc. Portland Oregon United States ADOBE INC. San Jose California United States ADOBE INC. Tokyo Japan Aetna Inc. Hartford Connecticut United States Agilent Technologies, Inc. Santa Clara California United States Ahold Delhaize Licensing Sarl Genève Genève Switzerland AIDA Cruises Rostock Germany Aigle International S.A.
    [Show full text]
  • Astellas Pharma US, Inc. Corporate Integrity Agreement
    CORPORATE INTEGRITY AGREEMENT BETWEEN THE OFFICE OF INSPECTOR GENERAL OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES AND ASTELLAS PHARMA US, INC. I. PREAMBLE Astellas Pharma US Inc. (Astellas) hereby enters into this Corporate Integrity Agreement (CIA) with the Office of Inspector General (OIG) of the United States Department of Health and Human Services (HHS) to promote compliance with the statutes, regulations, and written directives of Medicare, Medicaid, and all other Federal health care programs (as defined in 42 U.S.C. § 1320a-7b(f)) (Federal health care program requirements). Contemporaneously with this CIA, Astellas is entering into a Settlement Agreement with the United States. Prior to the Effective Date, Astellas established a compliance program that Astellas represents addresses all seven elements of an effective compliance program and that is designed to address compliance with Federal health care program requirements (Compliance Program). Astellas shall continue the Compliance Program throughout the term of the CIA and shall do so in accordance with the terms set forth below. Astellas may modify the Compliance Program as appropriate. However, at a minimum, Astellas shall ensure that during the term of this CIA, it shall maintain a compliance program to comply with the obligations set forth in this CIA. II. TERM AND SCOPE OF THE CIA A. The period of the compliance obligations assumed by Astellas under this CIA shall be five years from the effective date of this CIA. The “Effective Date” shall be the date on which the final signatory of this CIA executes this CIA. Each one-year period, beginning with the one-year period following the Effective Date, shall be referred to as a “Reporting Period.” Corporate Integrity Agreement Astellas Pharma US, Inc.
    [Show full text]
  • Holdings KL Allocation Fund, As of 3/31/20
    Holdings KL Allocation Fund, as of 3/31/20 Equity Securities % of Net Assets Country Sector CHUGAI PHARM CO 2.33 Japan Health Care FISHER & PAYKEL HE 1.79 New Zealand Health Care L'OREAL 1.72 France Consumer Staples COLOPLAST A/S 1.53 Denmark Health Care KONINKLIJKE DSM NV 1.44 Netherlands Materials INTEL CORP COM 1.13 United States Information Technology STERICYCLE INC 1.08 United States Industrials KAO CORP 1.08 Japan Consumer Staples SMC CORP 1.08 Japan Industrials UNI-CHARM CORP. 1.08 Japan Consumer Staples BIO-TECHNE CORP 1.07 United States Health Care DAIICHI SANKYO COM 1.06 Japan Health Care NOVARTIS AG 1.05 Switzerland Health Care GENTEX CORP 1.05 United States Consumer Discretionary JOHNSON & JOHNSON 1.04 United States Health Care 3M CO COM 1.04 United States Industrials SHIMADZU CORP 1.04 Japan Information Technology ALPHABET INC CAP STK CL A 1.04 United States Communication Services MERCK & CO INC COM 1.03 United States Health Care HISAMITSU PHARM CO 1.03 Japan Health Care PROCTER AND GAMBLE CO COM 1.03 United States Consumer Staples NISSIN FOOD HOLDINGS CO LTD 1.02 Japan Consumer Staples IROBOT CORP 1.01 United States Consumer Discretionary DAIKIN INDUSTRIES LTD 1.01 Japan Industrials NTT DOCOMO 1.00 Japan Communication Services GRIFOLS SA 1.00 Spain Health Care AIR LIQUIDE S.A. 1.00 France Materials BECTON DICKINSON & CO COM 1.00 United States Health Care NICE SYSTEMS LTD 0.99 Israel Information Technology VARIAN MED SYS INC COM 0.99 United States Health Care SYMRISE AG 0.98 Denmark Materials RECKITT BENCK GRP 0.98 United Kingdom Consumer Staples SUNTORY BEVERAGE & FOOD LTD 0.97 Japan Consumer Staples NOVO NORDISK A/S-B 0.94 Denmark Health Care SCHNEIDER ELECTRIC S.A.
    [Show full text]
  • Sony Corporation
    SONY CORPORATION Notice of the Ordinary General Meeting of Shareholders to be held on June 18, 2019 To the Registered Holders of American Depositary Receipts representing shares of Common Stock of Sony Corporation (the “Corporation”): The undersigned Depositary has received a notice that the Corporation has called an ordinary general meeting of shareholders to be held in Tokyo, Japan on June 18, 2019 (the “Meeting”) for the following purposes: MATTERS TO BE REPORTED: To receive reports on the business report, non-consolidated financial statements, consolidated financial statements, as well as audit reports on the consolidated financial statements by the Independent Auditors (certified public accountants) and the Audit Committee for the fiscal year ended March 31, 2019 (from April 1, 2018 to March 31, 2019) pursuant to the Companies Act of Japan. PROPOSALS TO BE ACTED UPON: 1. To elect 13 Directors. 2. To issue Stock Acquisition Rights for the purpose of granting stock options. EXPLANATION REGARDING THE SUBJECT MATTER OF THE MEETING MATTERS TO BE REPORTED: To receive reports on the business report, non-consolidated financial statements, consolidated financial statements, as well as audit reports on the consolidated financial statements by the Independent Auditors (certified public accountants) and the Audit Committee for the fiscal year ended March 31, 2019 (from April 1, 2018 to March 31, 2019). Note: The Consolidated Financial Statements are available on the Sony Investor Relations website. This document can be accessed at https://www.sony.net/SonyInfo/IR/stock/shareholders_meeting/Meeting102/ 1 PROPOSALS TO BE ACTED UPON: 1. To elect 13 Directors. The term of office of all 12 Directors currently in office will expire at the conclusion of the Meeting.
    [Show full text]
  • Notice of Convocation of the 12Th Term Annual
    Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders. In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail. [Translation] Notice of Convocation of the 12 th Term Annual Shareholders Meeting Date and Time: 10:00 a.m. on Monday, June 19, 2017 (Admission commences at: 9 a.m.) Place: “International Convention Center Pamir,” Grand Prince Hotel New Takanawa Matters to be resolved: Table of Contents First Proposal: Appropriation of Retained Earnings Notice of Convocation of the 12th Term Annual Shareholders Meeting ……………………………………………… 01 Second Proposal: Election of Six (6) Directors Reference Documents for Shareholders Meeting …………………… 07 Third Proposal: Provision of Bonus to Directors (Attachment) Business Report ……………………………………………………………… 19 Consolidated Financial Statements and Financial Statements …… 66 Audit Report …………………………………………………………………… 72 Securities Code: 4503 005_9778701172906.indd 1 2017/05/25 19:03:27 The Notice of Convocation (Securities Code 4503) May 30, 2017 To: Shareholders Notice of Convocation of the 12th Term Annual Shareholders Meeting Dear Madam/Sir: You are hereby notified that the 12th Term Annual Shareholders Meeting of Astellas Pharma Inc. (the “Company”) will be held as stated below. You are cordially invited to attend the meeting. In the event that you are unable to attend the aforesaid meeting, you may exercise your voting rights either by mail or by electronic or magnetic means (via Internet, etc.). In that case, the Company cordially requests that you consider the Reference Documents for Shareholders Meeting attached below and exercise the voting rights before 5:00 p.m.
    [Show full text]